EU panel recommends against nod for Puma Biotech's breast cancer drug

Feb 23 (Reuters) - A European Medicines Agency (EMA) panel on Friday recommended against approving Puma Biotechnology's lead breast cancer drug, an outcome the U.S drugmaker had signaled last month.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.